MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro

Journal of Pediatric Surgery

Volumn 37, Issue 11, 2002, Pages 1579-1584

  Warmann, Steven ^a,b   Göhring, Gudrun ^a,b   Teichmann, Birgit ^a,b   Geerlings, Heinz ^a,b   Fuchs, Jörg ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Human hepatoblastoma; MDR1 antagonizers; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ELACRIDAR; MULTIDRUG RESISTANCE PROTEIN 1; VALSPODAR; VERAPAMIL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0036830236     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1053/jpsu.2002.36188     Document Type: Article

References (35)

1. King D, Ortega J, Campell J: The surgical management of children with incompletely resected hepatic cancer is facilitated by intensive chemotherapy. J Pediatr Surg 26:1074-1981, 1991
2. Von Schweinitz D, Bürger D, Bode U, et al: Ergebnisse der studie HB-89 bei der behandlung maligner epithelialer lebertumoren des kindesalters und konzept eines neuen protokolls HB-94. Klin Pädiatr 206:282-288, 1994
3. Reynolds M, Douglass E, Finegold M: Chemotherapy can convert unresectable hepatoblastoma. J Pediatr Surg 27:1080-1084, 1992
4. Filler R, Ehrlich P, Grennberg M: Preoperative chemotherapy in hepatoblastoma. Surgery 110:519-522, 1992
5. Von Schweinitz D, Hecker H, Harms D: Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma. J Pediatr Surg 30:845-852, 1995
6. Von Schweinitz D, Byrd D, Hecker H, et al: Efficiency and toxicity of Ifosfamide, Cisplatin and Doxorubicin in the treatment of childhood hepatoblastoma. Eur J Cancer 33:1243-1249, 1997
7. Bader P, Fuchs J, Wenderoth M, et al: Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated in mice following treatment with doxorubicin or cisplatin. Anticancer Res 18:3127-3132, 1998
8. Germann UA: P-glycoprotein - A mediator of multidrug resistance in tumor cells. Eur J Cancer 6:927-944, 1996
9. Watariabe T, Tsuge H, Oh-Hara T, et al: Comparative study on reversal eficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 2:235-241, 1995
10. Tsuro T, Iida H, Tsukagosh S, et al: Overcoming of vincristine resistance in P833 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-72, 1981
11. Maliepaard M, van Gastelen MA, Tohgo A, et al: Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camtothecins in vitro using non-substrate drugs or the BCRP inhibitor GF 120918. Clin Cancer Res 7:935-941, 2001
12. Pietsch T, Fonatsch C, Albrecht S, et al: Characterization of the continous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 74:809-818, 1996
13. Ferry DR, Malkhandi PJ, Russell MA, et al: Allosteric regulation of [H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 49:1851-1861, 1995
14. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63, 1983
15. Witherspoon SM, Emerson DL, Kerr BM, et al: Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2:7-12, 1996
16. Hyafil F, Vergely C, Du Vignaud P, et al: In nitro and in vivo reversal of multidrug resistance by GF 120918, an acridone carboxamide derivate. Cancer Res 53:4595-4602, 1993
17. Beck I, Handgretinger R, Dopfer R, et al: Expression of MDR1, MRP, topoisomerase IIα/β and cyclin A in primary or relapsed states of acut lymphoblastic leukaemias. Br J Haematol 89:356-363, 1995
18. Scheffé H: The Analysis of Variance. New York, NY, Wiley, 1959
19. Dawson-Saunders B, Trapp RE: Basic and Clinical Biostatistics. Appleton and Lange, 1994
20. Brown J, Perilongo G, Shafford E, et al: Pretreatment prognostic factors for children with hepatoblastoma - Results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 36:1418-1425, 2000
21. Chan HS, DeBoer G, Haddad G, et al: Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am 9:275-318, 1995
22. Kuttesch JF Jr: Multidrug resistance in pediatric oncology. Invest New Drugs 14:55-67, 1996
23. Minemura M, Tanimura H, Tabor E: Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol 15:559-563, 1999
24. Goldstein LJ: MDRI gene expression in solid tumors. Eur J Cancer 6:1039-1050, 1996
25. Chico I, Kang MH, Bergan R, et al: Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol 19:832-842, 2001
26. Visani G, Milligan D, Leoni F, et al: Combined action of PSC 833 (valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia 15:764-771, 2001
27. Wallstab A, Koester M, Böhme M, et al: Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. Br J Cancer 79:1053-1060, 1999
28. Traunecker HCL, Stevens MCG, Kerr DJ, et al: The acridonecarboxamide GF 120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells. Br J Cancer 81:942-951, 1999
29. Watanabe T, Nakayama Y, Naito M, et al: Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Anti Cancer Drugs 7:825-832, 1996
30. Baekelandt M, Lehne G, Trope CG, et al: Phase I/II trial of the multidrug resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol 19:2983-2993, 2001
31. Arvelo F, Poupon MF, Bichat F, et al: Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts. Eur J Cancer 11:1862-1868, 1995
32. Brach DP, Massara FM, Besenton L, et al: Treatment of metastatic osteosarcoma with verapamil, cyclosporine and chemotherapy. A case report. Minerva Pediatr 47:147-151, 1995
33. Cowie FJ, Pinkerton CR, Phillips M, et al: Continous-infusion verapamil with etoposide in relapsed or resistant pediatric cancers. Br J Cancer 71:877-881, 1995
34. Warmann S, Hunger M, Teichmann B, et al: The role of the MDRI gene in the clinical course and an in vivo model of human hepatoblastoma. Presented at the 14th International Symposium on Pediatric Surgical Research, Madrid, Spain, October 5-6, 2001
35. Fuchs J, Wenderoth M, von Schweinitz D, et al: Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin and etoposide in heterotransplanted hepatoblastoma. Cancer 11:2400-2407, 1998